161 related articles for article (PubMed ID: 32225105)
1. Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia.
Tomasello L; Vezzalini M; Boni C; Bonifacio M; Scaffidi L; Yassin M; Al-Dewik N; Takam Kamga P; Krampera M; Sorio C
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225105
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
[TBL] [Abstract][Full Text] [Related]
3. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.
Vezzalini M; Mafficini A; Tomasello L; Lorenzetto E; Moratti E; Fiorini Z; Holyoake TL; Pellicano F; Krampera M; Tecchio C; Yassin M; Al-Dewik N; Ismail MA; Al Sayab A; Monne M; Sorio C
J Hematol Oncol; 2017 Jun; 10(1):129. PubMed ID: 28637510
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Ismail MA; Vezzalini M; Morsi H; Abujaber A; Al Sayab A; Siveen K; Yassin MA; Monne M; Samara M; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Sci Rep; 2021 Apr; 11(1):8833. PubMed ID: 33893334
[TBL] [Abstract][Full Text] [Related]
5. Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors.
Ismail MA; Nasrallah GK; Monne M; AlSayab A; Yassin MA; Varadharaj G; Younes S; Sorio C; Cook R; Modjtahedi H; Al-Dewik NI
Gene; 2022 Mar; 813():146101. PubMed ID: 34906644
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
7. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
Ismail MA; Samara M; Al Sayab A; Alsharshani M; Yassin MA; Varadharaj G; Vezzalini M; Tomasello L; Monne M; Morsi H; Qoronfleh MW; Zayed H; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Mol Genet Genomic Med; 2020 Oct; 8(10):e1319. PubMed ID: 32700424
[TBL] [Abstract][Full Text] [Related]
8. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112
[TBL] [Abstract][Full Text] [Related]
9. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.
Leo E; Mancini M; Aluigi M; Luatti S; Castagnetti F; Testoni N; Soverini S; Santucci MA; Martinelli G
PLoS One; 2013; 8(12):e81425. PubMed ID: 24339928
[TBL] [Abstract][Full Text] [Related]
11. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
12. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
13. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
14. Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
Yang KT; Wang MC; Chen JY; Hsu MC; Hung WC
J Cell Physiol; 2011 Nov; 226(11):2849-56. PubMed ID: 21935931
[TBL] [Abstract][Full Text] [Related]
15. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
16. Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients.
Ismail MA; Sorio C; Al-Dewik N
Cancer Control; 2022; 29():10732748221140201. PubMed ID: 36382578
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG.
Lombardi G; Latorre RV; Mosca A; Calvanese D; Tomasello L; Boni C; Ferracin M; Negrini M; Dewik NA; Yassin M; Ismail MA; Carpentieri B; Sorio C; Lecca P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077295
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.
Mancini M; Leo E; Takemaru K; Campi V; Castagnetti F; Soverini S; De Benedittis C; Rosti G; Cavo M; Santucci MA; Martinelli G
PLoS One; 2015; 10(7):e0131074. PubMed ID: 26147002
[TBL] [Abstract][Full Text] [Related]
19. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
